Interim Report January - March 2010

Interim Report January - March 2010

GROUP FINANCIAL PERFORMANCE JANUARY - MARCH
• Net sales amounted to SEK 20.3 million (23.0) 
• Operating income (EBIT) was SEK 4.6 million (7.4) 
• Net income after tax was SEK 2.1 million (4.4) 
• Results of investing activities SEK 0.0 million (0.0) 
• Earnings per share, basic and diluted was SEK 0.15 (0.34)
• Equity per share was SEK 34.35 (40.17) 
• Equity/assets ratio was 68 (68) percent

PARENT COMPANY FINANCIAL PERFORMANCE JANUARY-MARCH
• Results of investing activities SEK 0.0 million (0.0) 
• Other income was SEK 1.2 million (1.1)
• Net loss after tax amounted to SEK 2.6 million (-3.3) 

KEY EVENTS IN THE FIRST QUARTER
• Siemens chooses ONCOlog Medical's DIGNITY™ Carrier for its PET/CT solution
• AbSorber strengthens its presence in the U.S. by taking over Olerup Inc. in
collaboration with SSP Primers. 
• Likvor receives its first international order for the CELDA™ instrument as
well as two additional orders from hospitals in Sweden.

KEY EVENTS AFTER THE END OF THE REPORTING PERIOD
• Positive phase I results for AnaMar 
 

COMMENTS ON THE FIRST QUARTER 2010 FROM CEO INGEMAR LAGERLÖF
”Our focus during the first quarter, and going forwards, is on the
transplantation sector. Following the acquisition of the sales company in the
U.S., we now have the capacity to carry out forceful marketing efforts in our
core market. We are currently working inten-sively to build up an organization
in the U.S. and recruited a General Manager with extensive experience in
transplantation-sector product sales. We now have an in-house sales force that
covers all areas of the country. Sales of Olerup SSP's products continue to
increase and the drop in net sales during the first quarter can mainly be
attributed to currency effects. Performance is so promising that I, despite
positive developments in the vast majority of our other portfolio companies,
deem that the transplantation sector will become an increasingly important part
of a future LinkMed.”

For more information please contact:
Ingemar Lagerlöf, CEO, cell +46 (0)70-873 2733 or e-mail
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell +46 (0)70- 600 5364 or e-mail
okee.williams@linkmed.se


LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of thirteen companies, four in drug development and biotechnology and
nine in diagnostics and medical technology. The company's principal shareholders
are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB.
LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section
(ticker: LMED).